Shares of Indivior PLC (LON:INDV) have earned an average rating of “Buy” from the six ratings firms that are presently covering the firm, reports. One analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year target price among brokerages that have covered the stock in the last year is GBX 455.83 ($5.90).

Several research firms have recently commented on INDV. Jefferies Group LLC upped their price target on shares of Indivior PLC from GBX 490 ($6.34) to GBX 540 ($6.98) and gave the company a “buy” rating in a research report on Friday, August 11th. Numis Securities Ltd reaffirmed a “buy” rating and set a GBX 490 ($6.34) price target on shares of Indivior PLC in a research report on Wednesday, May 31st. Royal Bank Of Canada raised shares of Indivior PLC to an “outperform” rating and upped their price target for the company from GBX 390 ($5.04) to GBX 470 ($6.08) in a research report on Friday, July 28th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a GBX 500 ($6.47) price target on shares of Indivior PLC in a research report on Thursday, May 4th.

COPYRIGHT VIOLATION WARNING: “Indivior PLC (INDV) Receives Consensus Recommendation of “Buy” from Brokerages” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at

Shares of Indivior PLC (LON:INDV) traded down 0.27% during mid-day trading on Tuesday, hitting GBX 412.00. 1,385,191 shares of the company traded hands. The firm has a 50-day moving average of GBX 366.36 and a 200-day moving average of GBX 339.81. The stock’s market capitalization is GBX 2.97 billion. Indivior PLC has a one year low of GBX 266.60 and a one year high of GBX 421.50.

Indivior PLC Company Profile

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.

Analyst Recommendations for Indivior PLC (LON:INDV)

Receive News & Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related companies with's FREE daily email newsletter.